Patient-reported sexual outcomes after holmium laser enucleation of the prostate

A 3-year follow-up study

Dane E. Klett, Mark D. Tyson, Chinedu O. Mmeje, Rafael Nunez-Nateras, Yu Hui Chang, Mitchell R Humphreys

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective To evaluate the long-term patient reported sexual function outcomes of holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms secondary to prostate enlargement. Methods Three hundred ninety-three patients underwent a HoLEP between August 2007 and July 2013 and were reviewed in this retrospective analysis. Sexual function outcomes were assessed before HoLEP, and again at 3, 6, 12, 24, and 36 months after surgery using the International Index of Erectile Function 5 survey. International Prostate Symptom Scores (IPSS) were included for comparison and contextual functional outcome analysis. Results At the time of surgery, the mean age was 70.9 years (52.0-89.0 years), mean body mass index was 27.7 kg/m 2 (18.0-48.0 kg/m2), and mean prostate volume was 96.7 g (20.1-375.0 g). Mean International Index of Erectile Function 5 scores at 3 (13.3 ± 8.37), 6 (12.1 ± 8.76), 12 (12.1 ± 8.83), 24 (12.6 ± 8.80), and 36 months (12.5 ± 8.45) showed no significant change from baseline. There was, however, a significant improvement from baseline seen in IPSS over the same time period (P =.0001). Conclusion These data confirm HoLEP has a significant impact on IPSS and no adverse impact on long-term patient reported sexual function. We believe this series represents the largest cohort with the longest follow-up to date. It represents an important tool for preoperative patient counseling for those patients considering surgical therapy for benign prostatic hyperplasia.

Original languageEnglish (US)
Pages (from-to)421-426
Number of pages6
JournalUrology
Volume84
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Solid-State Lasers
Prostate
Patient Reported Outcome Measures
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Counseling
Body Mass Index
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Patient-reported sexual outcomes after holmium laser enucleation of the prostate : A 3-year follow-up study. / Klett, Dane E.; Tyson, Mark D.; Mmeje, Chinedu O.; Nunez-Nateras, Rafael; Chang, Yu Hui; Humphreys, Mitchell R.

In: Urology, Vol. 84, No. 2, 2014, p. 421-426.

Research output: Contribution to journalArticle

Klett, Dane E. ; Tyson, Mark D. ; Mmeje, Chinedu O. ; Nunez-Nateras, Rafael ; Chang, Yu Hui ; Humphreys, Mitchell R. / Patient-reported sexual outcomes after holmium laser enucleation of the prostate : A 3-year follow-up study. In: Urology. 2014 ; Vol. 84, No. 2. pp. 421-426.
@article{7e7dd7d08519432e862ce710a66e1cd2,
title = "Patient-reported sexual outcomes after holmium laser enucleation of the prostate: A 3-year follow-up study",
abstract = "Objective To evaluate the long-term patient reported sexual function outcomes of holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms secondary to prostate enlargement. Methods Three hundred ninety-three patients underwent a HoLEP between August 2007 and July 2013 and were reviewed in this retrospective analysis. Sexual function outcomes were assessed before HoLEP, and again at 3, 6, 12, 24, and 36 months after surgery using the International Index of Erectile Function 5 survey. International Prostate Symptom Scores (IPSS) were included for comparison and contextual functional outcome analysis. Results At the time of surgery, the mean age was 70.9 years (52.0-89.0 years), mean body mass index was 27.7 kg/m 2 (18.0-48.0 kg/m2), and mean prostate volume was 96.7 g (20.1-375.0 g). Mean International Index of Erectile Function 5 scores at 3 (13.3 ± 8.37), 6 (12.1 ± 8.76), 12 (12.1 ± 8.83), 24 (12.6 ± 8.80), and 36 months (12.5 ± 8.45) showed no significant change from baseline. There was, however, a significant improvement from baseline seen in IPSS over the same time period (P =.0001). Conclusion These data confirm HoLEP has a significant impact on IPSS and no adverse impact on long-term patient reported sexual function. We believe this series represents the largest cohort with the longest follow-up to date. It represents an important tool for preoperative patient counseling for those patients considering surgical therapy for benign prostatic hyperplasia.",
author = "Klett, {Dane E.} and Tyson, {Mark D.} and Mmeje, {Chinedu O.} and Rafael Nunez-Nateras and Chang, {Yu Hui} and Humphreys, {Mitchell R}",
year = "2014",
doi = "10.1016/j.urology.2014.04.042",
language = "English (US)",
volume = "84",
pages = "421--426",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Patient-reported sexual outcomes after holmium laser enucleation of the prostate

T2 - A 3-year follow-up study

AU - Klett, Dane E.

AU - Tyson, Mark D.

AU - Mmeje, Chinedu O.

AU - Nunez-Nateras, Rafael

AU - Chang, Yu Hui

AU - Humphreys, Mitchell R

PY - 2014

Y1 - 2014

N2 - Objective To evaluate the long-term patient reported sexual function outcomes of holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms secondary to prostate enlargement. Methods Three hundred ninety-three patients underwent a HoLEP between August 2007 and July 2013 and were reviewed in this retrospective analysis. Sexual function outcomes were assessed before HoLEP, and again at 3, 6, 12, 24, and 36 months after surgery using the International Index of Erectile Function 5 survey. International Prostate Symptom Scores (IPSS) were included for comparison and contextual functional outcome analysis. Results At the time of surgery, the mean age was 70.9 years (52.0-89.0 years), mean body mass index was 27.7 kg/m 2 (18.0-48.0 kg/m2), and mean prostate volume was 96.7 g (20.1-375.0 g). Mean International Index of Erectile Function 5 scores at 3 (13.3 ± 8.37), 6 (12.1 ± 8.76), 12 (12.1 ± 8.83), 24 (12.6 ± 8.80), and 36 months (12.5 ± 8.45) showed no significant change from baseline. There was, however, a significant improvement from baseline seen in IPSS over the same time period (P =.0001). Conclusion These data confirm HoLEP has a significant impact on IPSS and no adverse impact on long-term patient reported sexual function. We believe this series represents the largest cohort with the longest follow-up to date. It represents an important tool for preoperative patient counseling for those patients considering surgical therapy for benign prostatic hyperplasia.

AB - Objective To evaluate the long-term patient reported sexual function outcomes of holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms secondary to prostate enlargement. Methods Three hundred ninety-three patients underwent a HoLEP between August 2007 and July 2013 and were reviewed in this retrospective analysis. Sexual function outcomes were assessed before HoLEP, and again at 3, 6, 12, 24, and 36 months after surgery using the International Index of Erectile Function 5 survey. International Prostate Symptom Scores (IPSS) were included for comparison and contextual functional outcome analysis. Results At the time of surgery, the mean age was 70.9 years (52.0-89.0 years), mean body mass index was 27.7 kg/m 2 (18.0-48.0 kg/m2), and mean prostate volume was 96.7 g (20.1-375.0 g). Mean International Index of Erectile Function 5 scores at 3 (13.3 ± 8.37), 6 (12.1 ± 8.76), 12 (12.1 ± 8.83), 24 (12.6 ± 8.80), and 36 months (12.5 ± 8.45) showed no significant change from baseline. There was, however, a significant improvement from baseline seen in IPSS over the same time period (P =.0001). Conclusion These data confirm HoLEP has a significant impact on IPSS and no adverse impact on long-term patient reported sexual function. We believe this series represents the largest cohort with the longest follow-up to date. It represents an important tool for preoperative patient counseling for those patients considering surgical therapy for benign prostatic hyperplasia.

UR - http://www.scopus.com/inward/record.url?scp=84905120065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905120065&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2014.04.042

DO - 10.1016/j.urology.2014.04.042

M3 - Article

VL - 84

SP - 421

EP - 426

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -